Frequently Asked Questions

Conference Speakers

Cultural Speakers

Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.

At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:

- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Dr. Second Speaker Name
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
- -
Dr. Speakers Name Max Length
Speaker Credentials
View Registration Info
Speakers

Speakers (5191)

Sunday, 08 August 2021 11:17

Melissa L Johnson

Written by
Dr. Johnson joined Sarah Cannon in 2014 and serves as the program director of lung cancer research. Her responsibilities include leading the lung cancer clinical trial portfolio across the Sarah Cannon network. Dr. Johnson continues to work in early phase Drug Development as well as lead the Solid Tumor Immune Effector Cellular Therapy program at Sarah Cannon. She also currently serves as the Chair of the Cancer Committee at TriStar Centennial Medical Center in Nashville, Tennessee.

Dr. Johnson received her undergraduate degree from the University of North Carolina, Chapel Hill where she was a Morehead scholar, and her medical degree from the University of Pennsylvania. She completed her residency in internal medicine at New York Presbyterian/Weill Cornell Medical Center and her fellowship in medical oncology and hematology at Memorial Sloan Kettering Cancer Center where she also served as chief fellow for one year. She spent four years as a faculty member at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Feinberg School of Medicine, where she was a founding member of the Northwestern Medical Developmental Therapeutics Institute.

She is board certified in internal medicine and medical oncology. Additionally, she is a partner of Tennessee Oncology, PLLC.
Sunday, 08 August 2021 11:17

Edward B Garon

Written by
Dr. Garon received his MD degree from the Washington University School of Medicine in 1999, and his internal medicine training at the University of Chicago. He trained in Medical Oncology at UCLA, and joined the UCLA faculty in 2006. He also received a Masters' Degree in clinical investigation at UCLA. In 2008, he was appointed as an Assistant Professor of Medicine at the Geffen School of Medicine at UCLA in the Department of Medicine, Division of Hematology/Oncology and in 2014 he was promoted to Associate Professor of Medicine and he is now Professor of Medicine. Dr. Garon has been awarded the Diana Gordon Jonnson Award for Clinical Excellence in 2015. In addition to his clinical work, he also has an extensive focus in clinical and translational research. He has led studies that have led to FDA approvals of multiple drugs and companion diagnostic tests. He has received multiple foundations grants in addition to peer reviewed grants from governmental agencies, including NIH.
Sunday, 08 August 2021 11:17

Articulate Science

Written by
Sunday, 08 August 2021 11:17

Rafael Rosell

Written by
Sunday, 08 August 2021 11:17

Erik d'Hondt

Written by
Sunday, 08 August 2021 11:17

Jordi Codony-Servat

Written by
Sunday, 08 August 2021 11:17

Silvia Garcia-Roman

Written by
PhD in Chemistry and Chemical Engineering from the Sarriá Chemical Institute (IQS) of the Ramón Llull University in March 2017, in which I studied and developed organic compounds with antineoplastic activity. I am part of the laboratory team at the Dr. Rosell Oncology Institute. Specialist in human genetics. I have 11 years of experience in research laboratories at different universities (Barcelona University and Ramón Llull University), participating in various synthesis and characterization studies of organic and / or organometallic compounds and their interaction with nucleic acids and proteins, as well as studying the influence of copper and zinc in the protein b-amyloid implicated in neurodegenerative diseases and in cancer.
Page 327 of 371